← Eichor
Condition: Small Cell Lung Cancer Extensive Stage Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Small Cell Lung Cancer Extensive Stage

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Molecular Analysis and Treatment Options of SCLC
Phase N/A · 1 location(s) · Shanghai Chest Hospital · NCT05945745Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Phase 1 · 1 location(s) · Sichuan University · NCT06348797A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06437509WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06243003AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR
Phase 2 · 1 location(s) · Gruppo Oncologico Italiano di Ricerca Clinica · NCT06464068A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05924841Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cel
Phase 3 · 218 location(s) · Gilead Sciences · NCT06801834Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
NA · 1 location(s) · Ruijin Hospital · NCT05552846Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Phase 1 · 3 location(s) · Emory University · NCT05244239Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Phase 1/Phase 2 · 1 location(s) · Sichuan University · NCT06217757Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cel
Phase N/A · 1 location(s) · Shanghai Chest Hospital of Shanghai Jiao Tong University · NCT07070011The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
NA · 2 location(s) · University of Colorado, Boulder · NCT07636200Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Tr
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06698965A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Th
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07358676Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Phase 2 · 5 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07061535Tempus Small Cell Lung Cancer Observational Study (Sculptor)
Phase N/A · 11 location(s) · Tempus AI · NCT05257551Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
Phase 2 · 2 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07110103PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06429696A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06954246Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Phase 2 · 6 location(s) · Second Hospital of Shanxi Medical University · NCT06536868Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Phase 2 · 5 location(s) · Dwight Owen · NCT04919382Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT07244016Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Phase 1 · 31 location(s) · Amgen · NCT06598306Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) a
Phase 1/Phase 2 · 43 location(s) · National Cancer Institute (NCI) · NCT06287775Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Phase 1 · 6 location(s) · Amgen · NCT07531095MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Phase 2 · 4 location(s) · Hirva Mamdani · NCT05903092Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
Phase 2 · 18 location(s) · ETOP IBCSG Partners Foundation · NCT05718323First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Phase 2 · 1 location(s) · Xiaorong Dong · NCT05745350A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relaps
Phase 1/Phase 2 · 12 location(s) · Bristol-Myers Squibb · NCT07325136DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
Phase 3 · 242 location(s) · Boehringer Ingelheim · NCT07472517
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.